[1]陈 燕a,谷明莉a,叶 辛b,等.STING在原发性胆汁性肝硬化患者 外周血单个核细胞中的表达及临床意义[J].现代检验医学杂志,2016,31(03):33-35.[doi:10.3969/j.issn.1671-7414.2016.03.010]
　CHEN Yana,GU Ming-lia,YE Xinb,et al.Expression of STING in Peripheral Blood in Patients with Primary Biliary Cirrhosis and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2016,31(03):33-35.[doi:10.3969/j.issn.1671-7414.2016.03.010]
点击复制

STING在原发性胆汁性肝硬化患者 外周血单个核细胞中的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年03期
页码:
33-35
栏目:
论著
出版日期:
2016-06-15

文章信息/Info

Title:
Expression of STING in Peripheral Blood in Patients with Primary Biliary Cirrhosis and Its Clinical Significance
文章编号:
1671-7414(2016)03-033-03
作者:
陈 燕a; 谷明莉a; 叶 辛b; 李腾达a; 邓安梅a
第二军医大学长海医院a.实验诊断科;
b.输血科,上海 200433
Author(s):
CHEN Yana; GU Ming-lia; YE Xinb; LI Teng-daa; DENG An-meia
a.Department of Laboratory Diagnosis;
b.Department ofTransfusion Medicine, Changhai Hospital,Second Military Medical University,Shanghai 200433,China
关键词:
原发性胆汁性肝硬化;  刺激干扰素基因;  干扰素
分类号:
R575.22; R392.11
DOI:
10.3969/j.issn.1671-7414.2016.03.010
文献标志码:
A
摘要:
目的 探讨刺激干扰素基因(STING)在原发性胆汁性肝硬化(PBC)中的表达及其潜在的临床意义。方法 纳入2014年1月～2015年10月期间在上海长海医院和长征医院就诊的PBC患者28例,平均年龄32.5±11.3岁,纳入同期体检的健康对照28例,平均年龄37.5±13.7岁。分离单个核细胞(PBMC),采用实时荧光定量PCR检测STING mRNA表达水平; 采用Spearman检验分析STING表达水平与PBC患者临床指标的相关性; 随访5例初诊的PBC患者,观察临床治疗前后STING表达水平的变化。结果 与健康对照组相比,STING mRNA在PBC患者PBMC中显著增高,在Ⅲ期和Ⅳ期中的表达显著高于I期和Ⅱ期,差异有统计学意义(U=0.00,P<0.05)。STING mRNA水平与患者Mayo评分、GGT正相关(R=0.45,R=0.42,P<0.05),与AST,ALT和ALP无相关性(R=0.33,0.21,0.27,P>0.05)。临床治疗有效后,STING mRNA的表达量显著降低,差异有统计学意义(U=0.00,P<0.05)。结论 STING可能参与了PBC的发病机制。
Abstract:
Objective To explore the clinical significanceof STING in peripheral blood in patients with primary biliary cirrhosis.Methods Admitted 28 PBC patients hospitalized in Shanghai Changhai Hospital and Shanghai Changzheng Hospital from January 2014 to October 2015.Also enrolled 28 healthy controls.Baseline data and laboratory indicatorswere extracted,and STING mRNA expression was determined using q-PCR.The correlation between STING and clinical parameters were analyzed.The changes of STING mRNA in 5 followed-up patients with PBC were analyzed.Results Compared with healthy controls,STING mRNA was significantly increasedin PBC patients and was increased in patients with severer disease stages(U=0.00,P<0.05).STING was positively correlated with Mayo risk and GGT(R=0.45,R=0.42,P<0.05),and not AST,ALT or ALP(R=0.33,0.21,0.27,P>0.05).After therapy,STING mRNA were significantly reduced in 5 PBC patients(U=0.00,P<0.05).Conclusion STING may be involved in PBC pathogenesis.

参考文献/References:

[1] Czul F,Levy C.Novel therapies on primary biliary cirrhosis[J].Clinics in Liver Disease,2016,20(1):113-130.
[2] Cheung AC,Lapointe-Shaw L,Kowgier M,et al.Combined ursodeoxycholic acid(UDCA)and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J].Alimentary Pharmacology & Therapeutics,2016,43(2):283-293.
[3] Galani IE,Koltsida O,Andreakos E.Type III interferons(IFNs):EmergingMaster Regulators of Immunity[J].Advances in Experimental Medicine and Biology,2015(850):1-15.
[4] Lemos H,Huang L,McGaha T,et al.STING,nanoparticles,autoimmune disease and cancer:a novel paradigm for immunotherapy[J].Expert Review of Clinical Immunology,2015,11(1):155-165.
[5] Woo SR,Corrales L,Gajewski TF.The STING pathway and the T cell-inflamed tumor microenvironment[J].Trends Immunology,2015,36(4):250-256.
[6] Peng A,Ke P,Zhao R,et al.Elevated circulating CD14 low CD16+ monocyte subset in primary biliary cirrhosis correlates with liver injury and promotesTh1 polarization[J].Clinical and Experimental Medicine,2015[Epub ahead ofprint].
[7] Lazear HM,Nice TJ,Diamond MS.Interferon-lambda:Immune Functions at Barrier Surfaces and Beyond[J].Immunity,2015,43(1):15-28.
[8] McGlasson S,Jury A,Jackson A,et al.Type I interferon dysregulation and neurological disease[J].Nature Reviews Neurology,2015,11(9):515-523.
[9] Barber GN.STING:infection,inflammation and cancer[J].Nature ReviewsImmunology,2015,15(12):760-770.
[10] Liu X,Wang C.The emerging roles of the STING adaptor protein in immunity and diseases[J].Immunology,2016,147(3):285-291.

相似文献/References:

[1]钱 琤,谷明莉,陈 燕,等.原发性胆汁性肝硬化患者外周血单个核细胞IL-23p19表达增高及意义[J].现代检验医学杂志,2016,31(02):20.[doi:10.3969/j.issn.1671-7414.2016.02.006]
　QIAN Cheng,GU Ming-li,CHEN Yan,et al.High Expression of IL-23p19 in Peripheral Blood Mononuclear Cells of Patients with Primary Biliary Cirrhosis and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2016,31(03):20.[doi:10.3969/j.issn.1671-7414.2016.02.006]
[2]李腾达,刘挺挺,吴林洪,等.原发性胆汁性肝硬化患者外周血单个核细胞中Tim-1表达增高及其意义[J].现代检验医学杂志,2016,31(04):41.[doi:10.3969/j.issn.16717-414.2016.04.010]
　LI Teng-da,LIU Ting-ting,WU Lin-hong,et al.Increasing Expression of Tim-1 in Peripheral Blood Mononuclear Cell of Patients with Primary Biliary Cirrhosis and Its Significance[J].Journal of Modern Laboratory Medicine,2016,31(03):41.[doi:10.3969/j.issn.16717-414.2016.04.010]
[3]刘挺挺a,谷明莉a,张 蕾a,等.原发性胆汁性肝硬化患者外周血中性粒细胞/淋巴细胞比值及其临床意义[J].现代检验医学杂志,2016,31(05):127.[doi:10.3969/j.issn.1671-7414.2016.05.036]
　LIU Ting-tinga,GU Ming-lia,ZHANG Leia,et al.Clinical Significance of Neutrophils/Lymphocyte of Peripheral Blood in Patients with Primary Biliary Cirrhosis[J].Journal of Modern Laboratory Medicine,2016,31(03):127.[doi:10.3969/j.issn.1671-7414.2016.05.036]
[4]李腾达,陈 燕,龙曙萍,等.原发性胆汁性肝硬化患者外周血单个核细胞中IL-37表达增高及临床意义[J].现代检验医学杂志,2017,32(01):12.[doi:10.3969/j.issn.1671-7414.2017.01.004]
　LI Teng-da,CHEN Yan,LONG Shu-ping,et al.Increasing Expression of IL-37 in Peripheral Blood Mononuclear Cell of Patients with Primary Biliary Cirrhosis and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(03):12.[doi:10.3969/j.issn.1671-7414.2017.01.004]
[5]李腾达,陈 燕,谷明莉,等.PD-L1在原发性胆汁性肝硬化患者外周血单个核细胞中的变化及意义[J].现代检验医学杂志,2017,32(05):1.[doi:10.3969/j.issn.1671-7414.2017.05.001]
　LI Teng-da,CHEN Yan,GU Ming-li,et al.Change of PD-L1 in Peripheral Blood Mononuclear Cells of Patients with Primary Biliary Cirrhosis and Its Significance[J].Journal of Modern Laboratory Medicine,2017,32(03):1.[doi:10.3969/j.issn.1671-7414.2017.05.001]

备注/Memo

备注/Memo:
基金项目:973计划(2013CB531606),国家自然科学基金(81471605,81302579,81300748,81273282, 81202353,81401358),上海申康基金(CHDC22014014),军队科研基金(BWS14J023),长海医院1255学科建设计划(CH125530300),南京军区医药卫生科研基金(12MA056)。 作者简介:陈 燕,女,检验技师,主要从事临床检验诊断学工作。 作者简介:谷明莉,女,检验技师,主要从事临床检验诊断学工作,共同第一作者。 通讯作者:邓安梅,女,E-mail:amdeng70@163.com; 李腾达,女,E-mail:809009946@qq.com。
更新日期/Last Update: 2016-06-25